GlassScriptPhysician profile
Richard C Malara
NPI 1386634210
$8,327.57
in general payments reported to CMS, 2019-2025
27 companies · $661 in 2025
The $661 reported for 2025 was more than what 77% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $987 · 2020: $400 · 2021: $1,303 · 2022: $2,897 · 2023: $1,139 · 2024: $941 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,607.85 | 2019-2025 | Precision 1, Precision7, Dailies |
| Biotissue Holdings INC. | $1,509.33 | 2019-2025 | |
| Sight Sciences, INC. | $537.61 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $376.56 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $361.64 | 2019-2024 | |
| Coopervision INC. | $280.62 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Carl Zeiss Meditec, INC. | $280.02 | 2022 | |
| Notal Vision, INC. | $233.60 | 2022-2025 | Foresee Home |
| Bausch & Lomb Americas INC. | $212.79 | 2023-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.09 | 2019-2021 | |
| Dompe US, INC. | $176.41 | 2022-2025 | Oxervate |
| Allergan, INC. | $174.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $167.49 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $145.76 | 2021-2022 | |
| Shire North American Group INC | $129.59 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $128.79 | 2024-2025 | |
| Horizon Therapeutics Plc | $113.03 | 2023 | Tepezza |
| Harrow Eye, LLC | $111.42 | 2025 | Vevye |
| Astellas Pharma US INC | $99.68 | 2023 | |
| Abb Con-Cise Optical Group LLC | $96.22 | 2019-2022 | |
| Tearlab Corp | $95.24 | 2021-2022 | |
| Oyster Point Pharma, INC. | $89.78 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $60.83 | 2025 | Xdemvy |
| Maculogix, INC. | $53.33 | 2020 | |
| Optos, INC. | $47.62 | 2019 | |
| Amgen INC. | $24.67 | 2024 | Tepezza |
| Thea Pharma INC. | $19.49 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Malara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.